The DOI matches its Crossref record.
Breast Cancer: Current Molecular Therapeutic Targets and New Players
Abstract
Breast cancer is the most common cancer and the most frequent cause of cancer death among women worldwide. Breast cancer is a complex, heterogeneous disease classified into hormone-receptor-positive, human epidermal growth factor receptor-2 overexpressing (HER2+) and triple-negative breast cancer (TNBC) based on histological features. Endocrine therapy, the mainstay of treatment for hormone-responsive breast cancer involves use of selective estrogen receptor modulators (SERMs), selective estrogen receptor downregulators (SERDs) and aromatase inhibitors (AIs). Agents that target estrogen receptor (ER) and HER2 such as tamoxifen and trastuzumab have been the most extensively used therapeutics for breast cancer. Crosstalk between ER and other signalling networks as well as epigenetic mechanisms have been envisaged to contribute to endocrine therapy resistance. TNBC, a complex, heterogeneous, aggressive form of breast cancer in which the cells do not express ER, progesterone receptor or HER2 is refractory to therapy. Several molecular targets are being explored to target TNBC including androgen receptor, epidermal growth factor receptor (EGFR), poly(ADP-ribose) polymerase (PARP), and vascular endothelial growth factor (VEGF). Receptors, protein tyrosine kinases, phosphatases, proteases, PI3K/Akt signalling pathway, microRNAs (miRs) and long noncoding RNAs (lncRNAs) are potential therapeutic targets. miR-based therapeutic approaches include inhibition of oncomiRs by antisense oligonucleotides, restoration of tumour suppressors using miR mimics, and chemical modification of miRs. The lnRNAs HOTAIR, SPRY4-IT1, GAS5, and PANDAR, new players in tumour development and prognosis may have theranostic applications in breast cancer. Several novel classes of mechanism-based drugs have been designed and synthesised for treatment of breast cancer. Integration of nucleic acid sequencing studies with mass spectrometry-based peptide sequencing and posttranslational modifications as well as rational drug design will provide a more comprehensive understanding of the pathophysiology of breast cancer and help in evolving therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Risk Factors and Preventions of Breast Cancer
Sun, Y.-S., Zhao, Z., Yang, Z.-N., Xu, F., Lu, H.-J., Zhu, Z.-Y., Shi, W., Jiang, J., Yao, P.-P., & Zhu, H.-P. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.21635 · Cited by 2,003
Long Non-Coding RNA in the Pathogenesis of Cancers
Chi, Y., Wang, D., Wang, J., Yu, W., & Yang, J. (2019) · Cells · doi:10.3390/cells8091015 · Cited by 791
Deepak, K. G. K., Vempati, R., Nagaraju, G. P., Dasari, V. R., S., N., Rao, D. N., & Malla, R. R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104683 · Cited by 614
Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer
Dong, C., Wu, J., Chen, Y., Nie, J., & Chen, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.628690 · Cited by 375
SALMON: survival analysis learning with multi-omics neural networks on breast cancer
Huang, Z., Zhan, X., Xiang, S., Johnson, T. S., Helm, B., Yu, C. Y., Zhang, J., Salama, P., Rizkalla, M., Han, Z., et al. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00166 · Cited by 262
“Co-expression network analyses are used increasingly to reveal latent gene-gene interactions, biomarkers and novel gene functions (Horvath et al., 2012; Chandran et al., 2016; Han et al., 2016, 2017; Zhang and Huang, 2017; Xiang et al., 2018).”
Background
Metadata
- Authors
- Nagini, S.
- Venue
- Anti-Cancer Agents in Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2017-01-12
- Volume
- 17
- Issue
- 2
- Pages
- 152-163
- ISSN
- 1568-0118 (ISSN-L)
- 1871-5206
- OpenAlex
- W2416900233
- Cited by
- 503
- References
- 0
- FWCI
- 12.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Breast Cancer: Current Molecular Therapeutic Targets and New Players. https://app.cochat.ai/papers/10.2174/1871520616666160502122724
- The paper
- Nagini, S. (2017). Breast Cancer: Current Molecular Therapeutic Targets and New Players. Anti-Cancer Agents in Medicinal Chemistry. https://doi.org/10.2174/1871520616666160502122724
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.